TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01698827

Intervention type: OTHER
Intervention: Tube assessment visits
Description: Patients will return every 2 months for clinical questionnaire about leaks, obstructions or other dysfunctions of the tube. Objective tube examination for cracks, rupture, obstruction or dislodgement, along with replacement if necessary, will be carried out (total of 3 visits/6 months)

Intervention type: OTHER
Intervention: Tube assessment visits
Description: Patients will return every 2 months for clinical questionnaire about leaks, obstructions or other dysfunctions of the tube. Objective tube examination for cracks, rupture, obstruction or dislodgement, along with replacement if necessary, will be carried out (total of 3 visits/6 months)

Intervention type: OTHER
Intervention: Tube assessment visits
Description: Patients will return every 2 months for clinical questionnaire about leaks, obstructions or other dysfunctions of the tube. Objective tube examination for cracks, rupture, obstruction or dislodgement, along with replacement if necessary, will be carried out (total of 3 visits/6 months)

Intervention type: OTHER
Intervention: Tube assessment visits
Description: Patients will return every 2 months for clinical questionnaire about leaks, obstructions or other dysfunctions of the tube. Objective tube examination for cracks, rupture, obstruction or dislodgement, along with replacement if necessary, will be carried out (total of 3 visits/6 months)

Intervention type: OTHER
Intervention: Tube assessment visits
Description: Patients will return every 2 months for clinical questionnaire about leaks, obstructions or other dysfunctions of the tube. Objective tube examination for cracks, rupture, obstruction or dislodgement, along with replacement if necessary, will be carried out (total of 3 visits/6 months)
Study: NCT02926430

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF 5*10^10 vp
Description: Ad26.RSV.preF will be given at a concentration of 5\*10\^10 vp/0.5 milliliter (mL).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF 5*10^10 vp
Description: Ad26.RSV.preF will be given at a concentration of 5\*10\^10 vp/0.5 milliliter (mL).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF 1*10^11 vp
Description: Ad26.RSV.preF will be given at a concentration of 1\*10\^11 vp/0.5 milliliter (mL).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF 1*10^11 vp
Description: Ad26.RSV.preF will be given at a concentration of 1\*10\^11 vp/0.5 milliliter (mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo as formulation buffer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo as formulation buffer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo as formulation buffer.
Study: NCT04597684

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cemented Total Knee Arthroplasty
Description: Total Knee Arthroplasty (TKA) with cemented knees
Study: NCT01020643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: controlled administration of propofol
Description: comparison of propofol sedation
Study: NCT00864552

Intervention type: DRUG
Intervention: Kogenate (BAY14-2222)
Description: Patients with severe haemophilia A (\<2% FVIII:C baseline level) treated with Kogenate Bayer as their only source of recombinant FVIII
Study: NCT01095822

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren + Valsartan
Description: Comparison of combination (aliskiren + valsartan) therapy versus valsartan alone on hemostatic indices
Study: NCT00736112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Allergy Testing
Description: Food Allergy Diagnosis - blood drawn for food allergy testing at the time of surgery (bilateral myringotomy with tympanostomy tubes +/- adenoidectomy)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Description: Adenoidectomy to remove adenoid tissue. (Are adenoids a factor in OME (otitis media with effusion) or is food allergy diagnosis and treatment able to significantly prevent ROM (recurrent otitis media) after the tubes fall out?)
Study: NCT01095822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren + Valsartan
Description: Comparison of combination (aliskiren + valsartan) therapy versus valsartan alone on hemostatic indices
Study: NCT06083155

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary Function Test
Description: All participants are referred for a clinically indicated coronary function test

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary Function Test
Description: All participants are referred for a clinically indicated coronary function test

Intervention type: OTHER
Intervention: Patient questionnaires
Description: All participants that consent will receive yearly followup questionnaires for 5 years after their initial consent

Intervention type: OTHER
Intervention: Patient questionnaires
Description: All participants that consent will receive yearly followup questionnaires for 5 years after their initial consent
Study: NCT05293808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin 100 mg bis in die
Description: Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspririn 200 mg once daily
Description: Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin 100 mg once daily
Description: Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation.
Study: NCT04924218

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic surgical intervention
Description: The researchers investigated whether endoscopic surgical procedures performed due to various indications (hematuria, urinary tract stone, suspected bladder mass) in the patient group who had undergone radical prostatectomy, caused a change in urinary incontinence level. The researchers divided the endoscopic instruments used into 3 groups and evaluated whether there was a difference in urinary incontinence level between rigid cystoscope, flexible cystoscope and ureterorenoscope groups.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic surgical intervention
Description: The researchers investigated whether endoscopic surgical procedures performed due to various indications (hematuria, urinary tract stone, suspected bladder mass) in the patient group who had undergone radical prostatectomy, caused a change in urinary incontinence level. The researchers divided the endoscopic instruments used into 3 groups and evaluated whether there was a difference in urinary incontinence level between rigid cystoscope, flexible cystoscope and ureterorenoscope groups.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic surgical intervention
Description: The researchers investigated whether endoscopic surgical procedures performed due to various indications (hematuria, urinary tract stone, suspected bladder mass) in the patient group who had undergone radical prostatectomy, caused a change in urinary incontinence level. The researchers divided the endoscopic instruments used into 3 groups and evaluated whether there was a difference in urinary incontinence level between rigid cystoscope, flexible cystoscope and ureterorenoscope groups.
Study: NCT00510302

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire regarding melanoma risk-reduction.

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Interview via telephone about topics related to melanoma risk-reduction.
Study: NCT04211844

Intervention type: DRUG
Intervention: Sofosbuvir plus Ledipasvir
Description: 50 patients in the second group will receive 400 mg sofosbuvir plus ledipasvir 90 mg (Harvoni) once daily for 12 weeks.
Study: NCT00736112

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BMT
Description: The standard protocol for children presenting with initial Chronic OME is to perform a BMT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BMT
Description: The standard protocol for children presenting with initial Chronic OME is to perform a BMT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BMT
Description: The standard protocol for children presenting with initial Chronic OME is to perform a BMT
Study: NCT00693927

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unmanipulated PBSC after nonmyeloablative conditioning
Description: Conditioning regimen with 2 Gy TBI with or without added fludarabine (90 mg/m2).~Unmanipulated PBSC from HLA-identical sibling or HLA-matched related or unrelated donor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CD8-depleted PBSC after nonmyeloablative conditioning
Study: NCT04324138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jianpi Qinghua granules
Description: 3 times a day and 1 hour after a meal, for 4 weeks

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Jianpi Qinghua placebo granules
Description: 3 times a day and 1 hour after a meal, for 4 weeks
Study: NCT03341611

Intervention type: BEHAVIORAL
Intervention: Neuro-imaging during behavioral decision-making task
Description: All participants will make simple decisions while in a scanner.

Intervention type: BEHAVIORAL
Intervention: Neuro-imaging during behavioral decision-making task
Description: All participants will make simple decisions while in a scanner.
Study: NCT02894528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioMend and ReproBone
Description: Post-extraction sockets was filled by synthetic bone substitute ReproBone, and after the sockets were covered by a resorbable collagen membrane BioMend, which in turn was covered by a flap.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BioMend without ReproBone
Description: Post-extraction the socket was filled only by clot and covered by a resorbable collagen membrane BioMend, which in turn was covered by a flap.
Study: NCT01245205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt inhibitor MK2206
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01769144

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acticoat Absorbent
Description: wound dressing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BCT
Description: wound dressing
Study: NCT01450475

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic postconditioning
Description: At the time of reperfusion, remote ischaemic postconditioning will be induced by inflating a cuff around leg to 100 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times.
Study: NCT02575677

Intervention type: OTHER
Intervention: oxycodone
Description: oxycodone 0,1/kg up to 10 mg sc.
Study: NCT03714009

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fasting
Description: Periodic fasting last for 4weeks prior to the treatment cycle. The fasting method involves daily fasts of 14-16hours and restrict eating to an 8-10 hour eating window as 2-3 or more meals of balanced diet. Patients should take adequate water and non calorie beverages intake daily (2-3 liters).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No fasting
Description: Patients will not fast . But they will take balanced food and drink 2 to 3 liters of water and non caloric drinks all the day for 4 weeks
Study: NCT01619163

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: low dose, 7.5 mg/day
Study: NCT01272817

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Nonmyeloablative Allogeneic Transplant
Description: Cladribine 0.14 mg/kg/day for five days, melphalan 100 mg/m2 on one day

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Nonmyeloablative Allogeneic Transplant
Description: Total lymphoid irradiation 100cGy/day times 10 days (Monday through Friday)
Study: NCT00574457

Intervention type: OTHER
Group type: OTHER
Intervention: Carotid Ultrasound
Description: All subjects that meet the inclusion criteria at each certified site will be invited to participate and go through the same intervention (questionaire-scan-post scan questionaire and 1 month follow up questionaire)
Study: NCT00260429

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: collagenase clostridium histolyticum
Description: Subjects could have received up to three injections of AA4500/placebo into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: collagenase clostridium histolyticum
Description: Subjects could have received up to three injections of AA4500/placebo into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.
Study: NCT03714503

Intervention type: DEVICE
Group type: OTHER
Intervention: Retina re-attachment repair using C3F8 gas tamponade
Description: Assigning a one day post-operative head positioning
Study: NCT03703362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: 30 supervised training-sessions over 12 weeks
Study: NCT01047046

Intervention type: OTHER
Intervention: Retrospective chart review
Description: This study is a retrospective chart review including all patients who received surgical placement of a SNM device with Dr. Noblett from 2001 to the present.~The following data will be collected from patient charts: age at time of surgery, gravidity/parity, body mass index, pre-existing medical conditions/surgical history, current medications, menopausal status, form and severity of OAB symptoms, other previously or currently used interventions, method of SNM device placement, observed motor/sensory response, percent improvement of symptoms, follow-up OAB symptoms, frequency of InterStim settings adjustments, adverse events, significant changes in health, and incidence/reason for drop out.
Study: NCT03000634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Administered through a small tube that goes directly into the vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Administered as a subcutaneous injection under the skin

Intervention type: DRUG
Group type: OTHER
Intervention: Bortezomib
Description: Administered as a subcutaneous injection under the skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Capsule taken by mouth

Intervention type: DRUG
Group type: OTHER
Intervention: Lenalidomide
Description: Capsule taken by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Taken by mouth

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: Taken by mouth
Study: NCT00444080

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy
Description: Standard trabeculectomy procedure~1. Creation of a fornix or limbal based conjunctival flap in upper quadrants~2. Creation of a limbal-based scleral flap extending into clear cornea~3. Delicate application of MMC solution onto sclerectomy bed. (MMC concentration 0.4mg/ml for 1-3 minutes)~4. Creation of fistula 1mm x 2mm in size~5. Iridectomy~6. Suturing the scleral flap~7. Repositioning of conjunctiva with sutures After procedure, antibiotics \& steroids are administered topically; eye is covered with a pad - patient is discharged.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ex-PRESS mini shunt
Description: Ex-PRESS implantation procedure:~1. Creation of a fornix or limbal based conjunctival flap in upper quadrants~2. Creation of limbal-based scleral flap extending into clear cornea~3. Delicate application of MMC solution onto sclerectomy bed. (MMC concentration 0.4mg/ml for 1-3 minutes)~4. Penetration into anterior chamber using 23-25G needle, halfway between the white sclera and clear cornea (in the center of the grey zone);creation of track incision at limbus~5. Prior to implantation, a thorough mobility check should be performed~6. Implantation of Ex-PRESS implant loaded on its introducer, through that pre-incision~7. Withdrawal of introducer~8. Tucking plate under the scleral flap, and verification of its position~9. Suturing scleral flap After implantation procedure, antibiotics \& steroids administered topically; eye is covered with a pad - patient is discharged.
Study: NCT00510068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: A 10-mg dose of everolimus was given by continuous oral daily dosing of two 5-mg tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Everolimus Placebo
Description: a 10-mg dose of matching placebo to Everolimus was given by continuous oral daily dosing of two 5-mg tablets.
Study: NCT03684070

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Monitoring, peer support and motivational prompts
Description: The intervention compares the effect of technologically delivered motivational messages, and peer support upon daily step counts.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-monitoring
Description: Self-monitoring of data from wearable step count tracker
Study: NCT01241955

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video decision aid
Description: video of CPR
Study: NCT03293186

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MEDICLORE
Description: use MEDICLORE at the end of surgery as antiadhesive product
Study: NCT02711904

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extubation U
Description: Dose of remifentanil according to the randomization; the infusions that were used to reach the PC target were:~* 20 years old - 6.0 mcg/Kg/h~* 30 years old - 5.7 mcg/Kg/h~* 40 years old - 5.3 mcg/kg/h~* 50 years old - 5.0 mcg/kg/h~* 60 years old - 4.6 mcg/kg/h~* 70 years old - 4.3 mcg/kg/h~* 80 years old - 4.0 mcg kg/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extubation T
Description: Dose of infusion of remifentanil to reach a PC 3 - 4 ng/ml, in the following manner:~The assistant placed the infusion balloon in such a way that it could not be seen by the treating anesthesiologist, he proceeded to open the corresponding wrapping according to the consecutive which corresponds to the patient.~The remifentanil dose was adjusted according to the randomization:~* 20 years old - 9.0 mcg/Kg/h~* 30 years old - 8.5 mcg/Kg/h~* 40 years old - 8.0 mcg/kg/h~* 50 years old - 7.5 mcg/kg/h~* 60 years old - 7.0 mcg/kg/h~* 70 years old - 6.5 mcg/kg/h~* 80 years old - 6.0 mcg kg/h.
Study: NCT02878512

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCNL under General Anesthesia
Description: Patients undergoing percutaneous Nephrolithotomy received General anesthesia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Segmental Epidural Anesthesia
Description: Patients undergoing PCNL surgery received Segmental epidural anesthesia with 0.5% bupivacaine.
Study: NCT03748485

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: wait and watch
Description: clinical local advanced colorectal cancer (cTxN1/2M0) following preoperational adjuvant therapies and pathologically proved stageⅡ(pT0-3N0M0),without(wait and watch) adjuvant chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant chemotherapy
Description: clinical local advanced colorectal cancer (cTxN1/2M0) following preoperational adjuvant therapies and pathologically proved stageⅡ(pT0-3N0M0),with adjuvant chemotherapy
Study: NCT03883490

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG
Description: A 12-lead ECG will be taken for each participant.

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG
Description: A 12-lead ECG will be taken for each participant.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test and biobanking
Description: All patients will undergo venepuncture and blood sample will be taken for full blood count, renal function and plasma will be stored for future biomarker analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test and biobanking
Description: All patients will undergo venepuncture and blood sample will be taken for full blood count, renal function and plasma will be stored for future biomarker analysis.
Study: NCT00393029

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Beginning on day 1 or 2, administered subcutaneously at a dose of 5 mcg/kg/day (not to exceed 300 mcg/day); continue daily until neutrophil count \> 1.0 x 10\^9/L x 3 days or \> 5.0 x 10\^9/L.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 60 mg/kg/day x 2 days intravenously in 250ml dextrose 5% in water (D5W) with mesna 15 mg/kg/day x 2 days over 1 hour.
Study: NCT03883490

Intervention type: DIAGNOSTIC_TEST
Intervention: Trans-thoracic Echocardiogram
Description: A standard TTE will be undertaken to measure severity of AS as well as bi-ventricular function. Speckle-tracking data will be performed offline to assess diastolic function.

Intervention type: DIAGNOSTIC_TEST
Intervention: Trans-thoracic Echocardiogram
Description: A standard TTE will be undertaken to measure severity of AS as well as bi-ventricular function. Speckle-tracking data will be performed offline to assess diastolic function.

Intervention type: DIAGNOSTIC_TEST
Intervention: Vicorder recording
Description: Measurement of carotid-femoral PWV will be made using the Vicorder technique.

Intervention type: DIAGNOSTIC_TEST
Intervention: Vicorder recording
Description: Measurement of carotid-femoral PWV will be made using the Vicorder technique.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Patients will undergo a stress MRI scan of their heart and aorta on a 3T scanner, including 4D flow.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Patients will undergo a stress MRI scan of their heart and aorta on a 3T scanner, including 4D flow.
Study: NCT03792802

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic appendectomy port sites
Description: one group will have classic port sites ;.Port sites located 1 infraumbilical , 1 right lower quadrant and 1 left lower quadrent . one group will have same dermatome port sites ; One of the port will put in infraumbilical site and the other ones will put 10 cm right and left side from infraumbilical port

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic appendectomy port sites
Description: one group will have classic port sites ;.Port sites located 1 infraumbilical , 1 right lower quadrant and 1 left lower quadrent . one group will have same dermatome port sites ; One of the port will put in infraumbilical site and the other ones will put 10 cm right and left side from infraumbilical port